semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Uterine Cervical Neoplasms Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo)therapy including MRI guided BT Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix Staging according to FIGO and TNM guidelines MRI of pelvis at diagnosis is performed MRI, CT or PET-CT of the retroperitoneal space and abdomen at diagnosis is performed MRI with the applicator in place at the time of (first) BT will be performed Para-aortic metastatic nodes below L1-L2 are allowed Patient informed consent  Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix Metastatic disease above and beyond the retroperitoneal para-aortic L1-L2 interspace Previous pelvic or abdominal radiotherapy Previous total or partial hysterectomy Combination of preoperative radiotherapy with surgery Patients receiving BT only Patients receiving EBRT only Patients receiving neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/2). However, adjuvant chemotherapy in the form of 4 courses of 3 weekly Carboplatin (AUC 5) and Paclitaxel (155 mg/m2) is allowed according to departmental policy Contra indications to MRI
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Tumor years of age or older undergoing endoscopic endonasal transsphenoidal approach to pituitary resection for pituitary tumors of any pathology for the first time  patients who do not have a working understanding of English patients with known allergy to Merocel nasal packing
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adeno-squamous carcinoma of the uterine cervix Patients with histologically confirmed stage IB (IB3 excluded) and IIA1, according to the latest revision of the FIGO staging manual Patients undergoing either a Type B or C radical hysterectomy (Querleu and Morrow classification) Patients with adequate bone marrow, renal and hepatic function ECOG Performance Status of 0, 1 or 2 Patient must be suitable candidates for surgery Patients who have signed an approved Informed Consent Age 18 years or older  Any histology other than adenocarcinoma, squamous cell carcinoma or adeno-squamous carcinoma of the uterine cervix Tumor size greater than 4 cm FIGO stage II-IV (except IIA1) Patients with a history of pelvic or abdominal radiotherapy Patients who are pregnant Patients with contraindications to surgery Patients with evidence of metastatic disease by conventional imaging, enlarged pelvic or aortic lymph nodes > 2cm; or histologically positive lymph nodes Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator) Patients unable to withstand prolonged lithotomy and steep Trendelenburg position Patients with secondary invasive neoplasm in the last 5 years (except non-melanoma skin cancer, breast cancer T1N0M0 grade 1 or 2 without any signs of recurrence or activity)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Uterine Cervical Neoplasms Laparotomy Laparoscopy Survival Mortality Recurrence Pathological confirmed as uterine cervical cancer Having definite clinical information Having received radical hysterectomy or trachelectomy  Not satisfying any of the
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Adenocarcinoma Human Papillomavirus Genome-wide Association Study Whole Exome Sequencing Transcriptome Metabolome Tumorigenesis Prognosis Confirmed primary adenocarcinoma of the uterine cervix Signed an approved informed consents Feasible for biopsy  Not meeting all of the
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Sentinel Lymph Node HPV-Related Cervical Carcinoma Woman > 18 years of age diagnosed with cervical cancer and admitted for surgery with radical hysterectomy and removal of SLNs between October 2018 and June 2022  Woman < 18 years Women with late-stage cervical cancer, who are treated with radio and chemotherapy
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HPV-Related Carcinoma HPV-Related Malignancy cases Diagnosed with cervical cancer ≥ stage 1B between june 2018 and june 2020 > 18 years of age at the time of diagnosis There must be available cervical tissue material from the patient to analyse for HPV healthy controls Women > 18 years with no prior history of any cervical dysplasia CIN3 controls Women > 18 years Must have a histologically verified severe cervical dysplasia (CIN3) Is admitted for cervical conisation  cases < 18 years of age at time of cervical cancer diagnosis Cervical cancer < stage 1B healthy controls < 18 years of age Prior cervical dysplasia CIN3 controls < 18 years of age Women with only low grades of cervical dysplasia (CIN1 or CIN2) Women with HPV-negative cervical biopsies
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Hypertension Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy) Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure  Age < 18 years old Patients who cannot freely give their consent, or patients who refuse to participate Dialysis
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-53.0,  Uterine Cervical Dysplasia Papillomavirus Vaccines (vaccinated group) Thai women aged 20-45 years at the time of HPV vaccination Received at least 1 dose of bivalent or quadrivalent HPV vaccine at least 5 years ago Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result) (control group) Thai women without history of HPV vaccination Received Pap smear result at their ages 20-45 years at least 5 years ago Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result)  Known pregnancy History of hysterectomy or excisional treatment of the cervix Known increased risk of bleeding Not willing to provide written informed consent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Anesthesia, Local Age 18 and older Patients undergoing elective post-partum bilateral tubal ligation after vaginal delivery Patients receiving spinal epidural anesthesia with combination of bupivacaine and fentanyl  American Society of Anesthesiologists physical status score >3 Contraindications to neuraxial analgesia Patients in whom a combined spinal epidural cannot be performed Body mass index >40 kg/m2 Allergy or hypersensitivity to local anesthetics and fentanyl Severe liver, kidney or respiratory disease Inability to understand the study protocol Refusal to provide written consent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  NASH - Nonalcoholic Steatohepatitis Females of childbearing potential, 18 to 45 years of age, inclusive. Follicle-stimulating hormone levels may be used to confirm premenopausal status, including females who have had a hysterectomy with ovaries still intact. Women who otherwise meet and who have had tubal ligation, tubal occlusion, or bilateral salpingectomy will be allowed Body mass index between 18.0 and 32.0 kg/m2, inclusive In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations at Screening and Day -1 of the Lead-in Period Must not be pregnant or lactating, and must agree to use contraception Subjects must have documentation of normal results of up-to-date cervical cancer screening as specified in the American College of Obstetricians and Gynecologists guidelines: 1. Women aged < 21 years: no documentation required 2. Women aged 21 to 29: normal Pap smear test result within previous 3 years 3. Women aged 30 to 45: normal Pap smear test result and negative high-risk human papilloma virus test within previous 5 years, OR normal Pap smear test result within previous 3 years If documented results are not available at Screening, the subject must provide documentation of normal results prior to Day -1 of the Lead-in Period Able to comprehend and willing to sign an ICF Willing and able to adhere to assessments, prohibitions, and restrictions as described in this protocol  Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee) Are pregnant, breastfeeding, or are planning to conceive during the study Have been administered injectable contraceptives within 12 months prior to Day -1 of the Lead in Period, or had exposure to a hormonal intrauterine device or topical controlled delivery contraceptives (patch) within 3 months prior to Day -1 of the Lead-in Period
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-69.0,  Cervical Cancer Cervical Dysplasia Human Papillomavirus Infection All women aged between 30-69 years who are attending clinics in NUH  Women who are pregnant 2. Previous total hysterectomy 3. Previous history of cervical cancer 4. Virgin Intacto 5. Negative Pap smear less than 3 years ago
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Salpingectomy Sterilization, Tubal Women seeking for surgical sterilization during their cesarean section Elective and Category 2 or more planned cesarean sections  Clinical conditions that lead to planned cesarean hysterectomy such as placenta percreata History of ovarian cancer, previous chemotherapy or radiation Women who previously underwent sterilization
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-40.0,  Healthy Healthy men and women (non-smokers), BMI 18,5-30 kg/m2, and with no known metabolic disorders or food allergies will be recruited to the studies. The test subjects should consume a normal diet in accordance with the Nordic Nutrition Recommendations  Fasting blood glucose >6.1 mmol/L. Metabolic diseases or conditions. Food allergies or gastro intestinal conditions. Consumption of probiotics, antibiotics or other drugs
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-50.0,  Human Papillomavirus Infection women aged between 30 and 50 years sexually active women women who were first diagnosed with high risk HPV positive (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 82)  postmenopausal women (defined as those with at least 12 consecutive months of amenorrhea with no other medical cause and a follicle stimulating hormone (FSH) level of 40) women with chronic disease patients with antidepressant usage or patients with psychiatric disorders women who did not agree to participate in the study after reading the informed consent form women who admitted for follow up due to prior HPV infection women with only low-risk HPV (HPV 6, 11) positivity women with a sexual abuse history women with sexual penetration disorder
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Intraepithelial Neoplasia Patients aged ≥ 18 and ecog performance status ≤ 1 2. Patients with a diagnosis of high-grade cervical intraepithelial neoplasia or initially invasive cervical cancer (histological results ≥ CIN2 + and ≤ Ia1 according to the FIGO staging of cervical cancer) 3. No fever at the time of vaccination 4. No previous HPV vaccination 5. Ability to understand and write Italian 6. Signed informed and privacy consent  Patients enrolled in other clinical studies 2. History of allergic reaction or serious adverse events to previous vaccinations 3. Positive pregnancy test at the time of vaccination 4. Patient in treatment with immunosuppressive therapy 5. Subjects who received immunoglobulins or blood products in 3 months prior to vaccination. 6. Thrombocytopenia or any other clotting disorder that may lead to bleeding as a result of intramuscular administration 7. Clinical contraindicating the surgical act of conization 8. ECOG performance status ≥2
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA 1.2 Planned for radical radiotherapy and concurrent cisplatin chemotherapy 1.3 Age ≥ 18 years  Evidence of distant metastases (suspicious paraaortic nodes below the renal vessels allowed if they will be encompassed within the radiation field) Patients who have received any anticancer treatment for their cervical cancer Other cervical cancer tumor histologies (e.g. small cell, serous) Contraindications to 18FDG PET-CT Contraindication to radiotherapy (e.g. severe Crohn's disease) Contraindication to chemotherapy (e.g. non-reversible renal failure) History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 5 years Known pregnancy or lactating
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-66.0,  Cervical Cancer Screening Cervical Cancer women from 30 to 66 years old women living in french territorial division 37 ("Indre-et-Loire") women with a mobile phone in database women who do not perform a pap smear in the last 4 years women who do not answer to a first "invitation" letter to perform a pap smear  STOP SMS HPV cervical pathology during treatment Hysterectomy including cervix
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Uterine Diseases age ≥18 years BMI ≤40 kg/m2 indication for hysterectomy for benign disease or prophylactic surgery due to hereditary cancer indication for radical hysterectomy and/or pelvic-/para-aortic (sentinel-node) lymphadenectomy for cervical cancer indication for modified radical hysterectomy and/or pelvic-/para-aortic (sentinel-node) lymphadenectomy for endometrial cancer size of uterus and vagina allows for retrieval by the vaginal route in cancer patients written informed consent  known extensive intra-abdominal adhesions anaesthesiological contraindications to laparoscopy women with pacemaker or other implants where electrosurgery is to be avoided women with known defects of the hemostasis pregnancy other internal or anatomical that preclude a minimal invasive approach inability to understand patient information
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Human Papilloma Virus Cervical Neoplasm 65 years old patients with normal smear  Patients with invasive cervical cancer HIV-positive patients ASCUS and more risky premalignant lesions in cytology Over the age of 65 and Patients under 20 years of age patients with another known gynecological malignancy
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Cervical Cancer Human Papillomavirus Infection no history of hysterectomy or cervical cancer no Pap test in the past 3.5 years or Pap/HPV co-test in the past 5.5 years patient of Harris Health System in Harris County (Houston), Texas have at least 2 visits to ambulatory care within Harris Health System in the past 5 years be currently enrolled in a healthcare coverage or financial assistance plan accepted by Harris Health System  no valid telephone contact information unable to communicate in English or Spanish currently pregnant history of cervical dysplasia in the past 3.5 years